Phlow Corp. Achieves Key Milestone Toward Full Epinephrine Production — Made in America
The company has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) — a critical regulatory step. This product is now ready to be converted into a finished drug product.
PharmExec13d
FDA Approves ARS Pharmaceuticals’ neffy for Type 1 Allergic Reactions in Pediatric Patients
The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...
Medscape1mon
Epinephrine effects on major cell types of the aqueous outflow pathway: in vitro studies/clinical implications.
Continuous exposure of either cell type (ie, HTM or SCE cells) to EPI or ISO resulted in a four- to eightfold increase with a maximal effect measured around 10 hours and a half maximal effect at 2 ...
Healio13d
FDA approves epinephrine nasal spray for children aged as young as 4 years
The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...
Managed Healthcare Executive13d
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 ...
Pharmabiz12d
US FDA approves ARS Pharma’s neffy 1 mg to treat type I allergic reactions for paediatric patients weighing 15 to less than 30 kilograms
US FDA approves ARS Pharma’s neffy 1 mg to treat type I allergic reactions for paediatric patients weighing 15 to less than 30 kilograms: San Diego Friday, March 7, 2025, 09:00 ...